

Regent Pacific Continues Successful Efforts to Commercialise Fortacin™ in Asia

- *Licence agreement with Orient EuroPharma to commercialise Fortacin™ in Taiwan, Hong Kong, Macau, Malaysia, Brunei, Singapore, Philippines, Thailand and Vietnam*
- *Regent Pacific to receive up to US\$1.45 million in upfront licence payments and upon achievement of certain annual net sales milestones, dependent on the net sales achieved by Orient EuroPharma*
- *Regent Pacific to receive low teens royalty on net sales*
- *Licence agreement with China partner, Fosun, was signed on 3 December 2018*
- *Regent Pacific retains full commercial rights to Fortacin™ in all unlicensed countries, including the USA, Latin America, the Middle East and Sub-Saharan Africa*

(21 December 2018, Hong Kong) – Regent Pacific Group Limited (“Regent Pacific” or the “Company” and together with its subsidiaries, the “Group”; Hong Kong stock code: 00575), a specialist healthcare and life sciences investment group, has entered into a licence agreement (the “Licence Agreement”) with Orient EuroPharma Co., Ltd to commercialise Fortacin™ (by way of sale and distribution of Fortacin™) in Taiwan, Hong Kong SAR, Macau SAR, Malaysia, Brunei, Singapore, Philippines, Thailand and Vietnam, but excluding the People’s Republic of China, otherwise referred to herein as the “Territory”. Earlier this month, the Group signed a licence agreement with Wanbang Pharma, a subsidiary of Shanghai Fosun Pharma to launch Fortacin™ in the People’s Republic of China.

Fortacin™ is the first solution to premature ejaculation (PE) that does not act on the central nervous system and offers bona fide therapeutic efficacy that has been validated through extensive clinical trials in Europe, with over 23,500 doses delivered to trial participants. The solution is a topical spray containing low doses of lidocaine and prilocaine that take effect almost immediately upon application, giving users more control without reducing pleasure. Fully approved by the European Medicines Agency (EMA), Fortacin™ is now available in France, Germany, Italy, Portugal, Spain and in the UK from 2019 with it being rolled out in further European countries.

Jamie Gibson, Chief Executive Officer of Regent Pacific, said, *“Fortacin™ has commenced a randomized doubled blinded clinical trial in the US on 100 participants and will soon undergo further clinical trials in China, with visibility on approval by the US FDA in 2021. Recently signed license agreements with Wanbang Pharma and Orient EuroPharma should open the door to Asia-wide availability in the coming years, with first roll-out scheduled in Hong Kong and Macau in 2019, and further launches planned for Taiwan and other countries in Southeast Asia in 2020.”*

Regent Pacific will be eligible to receive payments of up to US\$1.45 million (or approximately HK\$11,310,000) excluding royalties.

Under the terms of the Licence Agreement, Regent Pacific will receive:

- a payment of US\$300,000 (or approximately HK\$2,340,000) following the effective date of the Licence Agreement or manufacturing and supply agreement with PSNW, whichever comes later;
- a payment of US\$300,000 (or approximately HK\$2,340,000) upon receipt from the Taiwan Food and Drug Administration of the approval for the importation of the licensed product into Taiwan;
- A possible payment of up to US\$850,000 (or approximately HK\$6,630,000) in total upon achievement of certain annual net sales milestones, dependent on the net sales achieved by Orient EuroPharma;
- Low teens royalty on net sales; and
- a lower percentage royalty on net sales will apply in certain circumstances where a generic product has successfully entered and impacted the market in the Territory.

Under the License Agreement, Orient EuroPharma will assume responsibility for filing applications for, and obtaining any and all regulatory approvals required under applicable law to commercialise Fortacin™ in the Territory, at its own expense. The License Agreement is for an indefinite period and contains customary provisions in respect of termination.

Orient EuroPharma has entered into a manufacturing and supply agreement with PSNW on 21 December 2018 for the manufacture and supply of Fortacin™ product for Orient EuroPharma.

The Group also remains in active discussions with possible commercial partners for the sale and distribution of Fortacin™ in the remaining key markets of North America, Latin America and the rest of the Asia Pacific region.

– END –

For further information, please contact:

Finsbury

Sheena Shah (Hong Kong)
t : +852 3166 9855
e : sheena.shah@finsbury.com

Alastair Hetherington (United Kingdom)
t: +44 20 7251 3801
e: alastair.hetherington@finsbury.com

Rafaella Lee (Hong Kong)
t : +852 3166 9882
e : rafaella.lee@finsbury.com

About Regent Pacific

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings plc, is a specialty pharmaceutical company whose core product Fortacin™ is the first EU approved topical prescription treatment for Premature Ejaculation that does not act on the central nervous system in the key European Union countries of France, Germany, Italy, Portugal and Spain from February 2018. It is to be launched subsequently in the United Kingdom in January 2019 and thereafter it will be rolled out in Czech Republic, Slovakia, Poland, Ireland, Romania and Greece, the rest of Europe, Russia, CIS and certain countries of North Africa. The Group has a strong track record of investments and has returned approximately US\$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

About Orient EuroPharma

Founded in 1982, Orient EuroPharma Co., Ltd (OEP) is a multinational pharmaceutical company and listed on the Taiwan Security Exchange Market. The consolidated net sales exceeded US\$169 million (approximately NT\$5.2 billion) in the 2017 financial year. Currently, OEP has more than 900 employees worldwide, in which over 40% are overseas employees. OEP markets pharmaceutical and oncology medicine, adult and baby nutrition, anti-aging products in Taiwan, China and the ASEAN market. Subsidiaries of the group: Orient Pharma and OP NanoPharma, focusing on new drug development and manufacture. To vertically integrate pharmaceutical R&D, clinical development, manufacture and marketing is the strength of OEP group. OEP is steadily cultivating the Asia-Pacific market and reaching the goal of being a benchmark enterprise in the Asia Pacific region.

Forward Looking Statements

This announcement, including any information included or incorporated by reference in this announcement, contains statements about Regent Pacific that are or may be forward looking statements. Such forward looking statements involve risks and uncertainties that could significantly affect expected results and are based on certain key assumptions. Many factors could cause actual results to differ materially from those projected or implied in any forward looking statement. Much of the risk and uncertainty relates to factors that are beyond Regent Pacific's abilities to control or estimate precisely, such as future market conditions and the behaviours of other market participants, and therefore undue reliance should not be placed on such statements. Neither Regent Pacific nor any of its associates or directors, officers, employees, managers, agents, representatives, partners, members, consultants or advisers: (i) provide any representation, warranty, assurance or guarantee that the occurrence of the events expressed or implied in any forward looking statement will actually occur; nor (ii) assume any obligation to, and do not intend to, revise or update these forward looking statements, except as required pursuant to applicable law, the HK Listing Rules or other applicable regulation. Regent Pacific disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law, the HK Listing Rules or other applicable regulation.

No Profit Forecasts or Estimates

No statement in this announcement is intended as a profit forecast or estimate for any period and no statement in this announcement should be interpreted to mean that earnings or earnings per share for Regent Pacific for the current or future financial years would necessarily match or exceed the historical published earnings or earnings per share for Regent Pacific. Regent Pacific does not undertake to update information contained in this announcement, except as required by applicable law, the HK Listing Rules or other applicable regulation.